CV Sciences, a manufacturer and supplier of hemp-based CBD oil and pharmaceutical therapeutics, announced today that it has applied to list the company’s common stock on the NASDAQ Capital Market. Acceptance to the market will be contingent on meeting NASDAQ’s minimum listing requirements. While CV Sciences is being evaluated, the company will continue trading on the OTC Markets under the symbol CVSI. If approved, CV Sciences would join a growing list of cannabis-based companies up-listing to larger exchanges, such as the Canadian company Tilray; which recently went public on the NASDAQ and saw its valuation soar at the announcement. Tilray is currently valued at approximately $3 billion.
To read more, visit the original post on New Cannabis Ventures.
To learn more about CV Sciences and the sales leaders in the hemp-derived CBD industry, check out The CBD Report 2018.
Please comment below—we’d love to hear your thoughts.